Industry Clinical Trials Stopped Early (% of Trials Ended)

## What this measures

Of the company-led interventional trials that ended over the last 12 months, the share that were terminated (stopped early) rather than completed, in percent.

## Why it matters

Companies stop trials when the science disappoints, when patients cannot be found or when money or strategy changes. A rising share of early stops is an early sign of pipeline cuts and funding stress in pharma and biotech.

## How to read it

Higher means more trials stopped early. See why with the stopped-reason shares (clinicaltrials.stopped_reason.business_share, enrollment_share and safety_efficacy_share).

## What it does not say

A registration is a plan, not a result: some registered trials never start, and size, cost and odds of success differ widely. Being listed does not mean a study was reviewed by the U.S. government.

## How it's built

Terminated trials divided by terminated plus completed trials. Company-led interventional trials that ended with an actual completion date, counted in the month they ended and summed over the 12 months to the month shown (so each point is a 12-month window). Trials report their ending late, so the newest three complete months are not published, and the latest points can still move a little as reports arrive. Records are read from the API each week. History from January 2010.

## Source

ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly by /api/cron/clinicaltrials-pipeline-sync. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.